−0.8%
since Oct 8
The idea
I believe medicine looks fundamentally different by 2045, with diseases edited at the genetic root, drugs designed by AI, cancers caught at stage one, and obesity treated as a solvable drug problem rather than a lifestyle issue. The portfolio spreads across gene editing, AI drug discovery, early detection, and metabolic medicine, with roughly a quarter in the tools and equipment makers that get paid regardless of which specific cure wins.
What it owns
- These companies supply the instruments, reagents and equipment that labs and drugmakers need regardless of which treatments succeed. · Thermo Fisher ScientificIt sells lab supplies, instruments and clinical trial services to drugmakers across all research areas, so it profits regardless of which cures win., DanaherIt manufactures equipment and supplies for growing and purifying biologic drugs and gene therapies at scale., Agilent TechnologiesIt makes instruments that labs use to test and measure drugs and biological samples, providing steady foundation through drug development cycles., West Pharmaceutical ServicesIt makes the vials, stoppers and injection components for injectable drugs, and today's obesity therapies are mostly delivered by injection., IlluminaIts sequencing machines read DNA and serve as the foundation for both gene editing research and early cancer detection tests., 10x GenomicsIt sells tools that study biology one cell at a time, helping researchers identify targets for gene editing or therapeutic intervention.28%
- Gene editing and genetic medicines aim to fix disease at its root with a single treatment instead of managing symptoms. · Vertex PharmaceuticalsIt co-developed and sells the first approved CRISPR treatment, proving that genetic editing can become a sustainable business., CRISPR TherapeuticsIt co-developed the first approved CRISPR treatment and is advancing additional gene-edited therapies through clinical trials., Regeneron PharmaceuticalsIt operates one of the largest human genetics databases and uses it to identify drug targets more efficiently than traditional methods., Beam TherapeuticsIt uses base editing to change single DNA letters without cutting both strands, aiming for greater precision than earlier gene editing approaches., Intellia TherapeuticsIt edits genes directly inside the body with a single infusion rather than removing cells first, representing the boldest approach to fixing disease at its root.24%
- Robotic surgery and wearable devices are changing how care gets delivered in operating rooms and at home. · Intuitive SurgicalIt makes the da Vinci surgical robots that are becoming the standard for minimally invasive procedures in hospitals., DexComIts continuous glucose monitors let people track blood sugar in real time, turning metabolic disease management into a data-driven practice., InsuletIt makes the Omnipod, a tubeless insulin pump that works with glucose monitors for more automated diabetes care management.13%
- Companies using computation and patient data to design and select drugs are replacing traditional hand-based testing methods. · Tempus AIIt combines genetic testing with a large clinical database and uses AI to guide treatment selection and drug research for pharmaceutical companies., Recursion PharmaceuticalsIt represents the direct bet that AI can design drug candidates faster and more effectively than traditional laboratory methods., SchrodingerIt sells physics-based software that helps drugmakers design molecules on computers and also develops its own drug candidates.10%
- Obesity and metabolic drugs are reshaping medicine and reaching hundreds of millions of patients worldwide. · Eli LillyIt leads in obesity and metabolic drugs, which are already transforming how medicine treats weight as a disease rather than a behavioral issue.8%
- Blood tests that identify cancer and genetic conditions early make treatment far cheaper and more effective. · Guardant HealthIt develops blood tests that detect cancer DNA, including screening tests designed to identify cancer at its earliest stages., NateraIt reads DNA fragments in blood to detect recurring cancer and screen pregnancies, catching disease earlier when treatment is more effective.8%
- Cash8%